Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic

Introduction: The COVID-19 pandemic hit the United Kingdom in early 2020. High infection rates prompted concern for immunocompromised patients, including patients with AML receiving intensive chemotherapy. CPX-351 (Europe: Vyxeos ® Liposomal; US: Vyxeos ®), a dual-drug liposomal encapsulation of dau...

Descripción completa

Detalles Bibliográficos
Autores principales: Munisamy, Sreetharan, Choudhuri, Satarupa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
615.Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701482/
http://dx.doi.org/10.1182/blood-2021-146524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701482/
http://dx.doi.org/10.1182/blood-2021-146524

Ejemplares similares